Russian biosimilar manufacturer Biocad has had its rituximab equivalent approved by the Cuban Ministry of Health, and will begin issuing the drug to patients by the end of 2018.
In Cuba, around 1,000 people per year are diagnosed with non-Hodgkins lymphoma and some 700 die as a result of the disease.
Rituximab can also be used to treat rheumatiod arthritis, which around 1% of Cubans also suffer from, leaving them at risk of rapid degeneration into disability if left untreated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze